Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma

NCT00826241 is registered in ClinicalTrials.gov with National Institutes of Health Clinical Center (CC) as lead sponsor.

NCT NCT00826241
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00826241 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma
Lead sponsor
National Institutes of Health Clinical Center (CC)
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2009
Completion date
July 31, 2018
Enrollment
58 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

brain tumors, spinal cord tumors